| Item Type | Name |
|
Concept
|
Acute Disease
|
|
Concept
|
Adenocarcinoma
|
|
Concept
|
Age Factors
|
|
Concept
|
Acetylation
|
|
Concept
|
Acquired Immunodeficiency Syndrome
|
|
Concept
|
Addison Disease
|
|
Concept
|
Administration, Inhalation
|
|
Concept
|
Antigens, Neoplasm
|
|
Concept
|
Antibiotics, Antineoplastic
|
|
Concept
|
Adrenal Cortex Diseases
|
|
Concept
|
Aldosterone
|
|
Concept
|
Androstenols
|
|
Concept
|
Acetaminophen
|
|
Concept
|
Adenoma
|
|
Concept
|
Transaminases
|
|
Concept
|
Analgesics, Opioid
|
|
Concept
|
Breast Neoplasms
|
|
Concept
|
Ambulatory Care
|
|
Concept
|
Adrenocorticotropic Hormone
|
|
Concept
|
Alcohol Dehydrogenase
|
|
Concept
|
Acetyltransferases
|
|
Concept
|
Aerosols
|
|
Concept
|
Blindness
|
|
Concept
|
Anticonvulsants
|
|
Concept
|
Antigens, Surface
|
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Arylamine N-Acetyltransferase
|
|
Concept
|
Busulfan
|
|
Concept
|
Carbazoles
|
|
Concept
|
Carcinoma, Squamous Cell
|
|
Concept
|
Aminopyridines
|
|
Concept
|
Analgesics
|
|
Concept
|
Androstadienes
|
|
Concept
|
Androstenes
|
|
Concept
|
Animals
|
|
Concept
|
Anticoagulants
|
|
Concept
|
Antifungal Agents
|
|
Concept
|
Anesthesiology
|
|
Concept
|
Anthraquinones
|
|
Concept
|
Antimetabolites, Antineoplastic
|
|
Concept
|
Antineoplastic Combined Chemotherapy Protocols
|
|
Concept
|
Carcinoma
|
|
Concept
|
Aminoquinolines
|
|
Concept
|
Chromosomes, Human, Pair 11
|
|
Concept
|
Antihypertensive Agents
|
|
Concept
|
Analysis of Variance
|
|
Concept
|
Anesthetics
|
|
Concept
|
Anthropometry
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Antigens, Differentiation, T-Lymphocyte
|
|
Concept
|
Codeine
|
|
Concept
|
Asthma
|
|
Concept
|
Cyclosporins
|
|
Concept
|
Anti-Inflammatory Agents
|
|
Concept
|
Antidotes
|
|
Concept
|
Aryl Hydrocarbon Hydroxylases
|
|
Concept
|
B-Lymphocytes
|
|
Concept
|
Base Sequence
|
|
Concept
|
Benzamides
|
|
Concept
|
Carmustine
|
|
Concept
|
Cell Count
|
|
Concept
|
Bayes Theorem
|
|
Concept
|
Aspartate Aminotransferases
|
|
Concept
|
Dipeptides
|
|
Concept
|
Body Height
|
|
Concept
|
Azacitidine
|
|
Concept
|
Pan troglodytes
|
|
Concept
|
Carcinoma, Renal Cell
|
|
Concept
|
Astrocytoma
|
|
Concept
|
Drug Packaging
|
|
Concept
|
Bilirubin
|
|
Concept
|
Blast Crisis
|
|
Concept
|
Bleomycin
|
|
Concept
|
Biopsy
|
|
Concept
|
Body Weight
|
|
Concept
|
Cancer Care Facilities
|
|
Concept
|
Carcinoma, Non-Small-Cell Lung
|
|
Concept
|
Cattle
|
|
Concept
|
Catheterization, Central Venous
|
|
Concept
|
Ethics, Medical
|
|
Concept
|
Chromosomes, Human, Pair 21
|
|
Concept
|
Complement System Proteins
|
|
Concept
|
Carbon Radioisotopes
|
|
Concept
|
Flavonoids
|
|
Concept
|
Floxuridine
|
|
Concept
|
Colonic Neoplasms
|
|
Concept
|
Coma
|
|
Concept
|
Uterine Cervical Neoplasms
|
|
Concept
|
Chicago
|
|
Concept
|
Burkitt Lymphoma
|
|
Concept
|
Chromium
|
|
Concept
|
Leucovorin
|
|
Concept
|
Colonic Polyps
|
|
Concept
|
C-Reactive Protein
|
|
Concept
|
Career Choice
|
|
Concept
|
Glutathione Transferase
|
|
Concept
|
Crigler-Najjar Syndrome
|
|
Concept
|
Chromatography, Ion Exchange
|
|
Concept
|
Circadian Rhythm
|
|
Concept
|
Hemoglobins
|
|
Concept
|
Contrast Media
|
|
Concept
|
Demography
|
|
Concept
|
Hockey
|
|
Concept
|
Cosyntropin
|
|
Concept
|
Hydroxylation
|
|
Concept
|
Hymecromone
|
|
Concept
|
Dexamethasone
|
|
Concept
|
Drug Industry
|
|
Concept
|
Drug Synergism
|
|
Concept
|
Immunosuppressive Agents
|
|
Concept
|
Infusion Pumps
|
|
Concept
|
Interleukin-2
|
|
Concept
|
Critical Care
|
|
Concept
|
Cytidine Deaminase
|
|
Concept
|
Cytochrome P-450 Enzyme System
|
|
Concept
|
Decision Support Techniques
|
|
Concept
|
Dose-Response Relationship, Radiation
|
|
Concept
|
Child, Preschool
|
|
Concept
|
DNA, Neoplasm
|
|
Concept
|
Dogs
|
|
Concept
|
Drug Hypersensitivity
|
|
Concept
|
Cyclohexanecarboxylic Acids
|
|
Concept
|
Cyclophosphamide
|
|
Concept
|
Daunorubicin
|
|
Concept
|
Dehydroepiandrosterone
|
|
Concept
|
Europe
|
|
Concept
|
Tegafur
|
|
Concept
|
Patient Care
|
|
Concept
|
Glucocorticoids
|
|
Concept
|
Hemoglobin A
|
|
Concept
|
Kidney Neoplasms
|
|
Concept
|
Enzyme Inhibitors
|
|
Concept
|
Erythrocyte Count
|
|
Concept
|
Leukemia
|
|
Concept
|
Delivery of Health Care
|
|
Concept
|
Chromatography, High Pressure Liquid
|
|
Concept
|
Chromatography, Liquid
|
|
Concept
|
Gas Chromatography-Mass Spectrometry
|
|
Concept
|
Erythropoietin
|
|
Concept
|
Etoposide
|
|
Concept
|
Coformycin
|
|
Concept
|
Cytarabine
|
|
Concept
|
DNA Topoisomerases, Type II
|
|
Concept
|
Double-Blind Method
|
|
Concept
|
Drug Utilization
|
|
Concept
|
Diphtheria Toxin
|
|
Concept
|
Food
|
|
Concept
|
Inactivation, Metabolic
|
|
Concept
|
Indicators and Reagents
|
|
Concept
|
Indoles
|
|
Concept
|
Interferons
|
|
Concept
|
Introns
|
|
Concept
|
Electrocardiography
|
|
Concept
|
Methyltransferases
|
|
Concept
|
Microtubule-Associated Proteins
|
|
Concept
|
Fluorouracil
|
|
Concept
|
Food Labeling
|
|
Concept
|
Decision Making
|
|
Concept
|
Deoxyadenosines
|
|
Concept
|
Glioma
|
|
Concept
|
Glioblastoma
|
|
Concept
|
Glomerular Filtration Rate
|
|
Concept
|
Fasting
|
|
Concept
|
Feasibility Studies
|
|
Concept
|
Neovascularization, Pathologic
|
|
Concept
|
Neural Conduction
|
|
Concept
|
Terminology as Topic
|
|
Concept
|
Jaundice
|
|
Concept
|
Karyotyping
|
|
Concept
|
Kidney Diseases
|
|
Concept
|
Killer Cells, Natural
|
|
Concept
|
Forced Expiratory Volume
|
|
Concept
|
Formaldehyde
|
|
Concept
|
Government Agencies
|
|
Concept
|
Heart Ventricles
|
|
Concept
|
Electroencephalography
|
|
Concept
|
DNA Topoisomerases, Type I
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Drug Labeling
|
|
Concept
|
Hydralazine
|
|
Concept
|
Hyperlipidemias
|
|
Concept
|
Life Expectancy
|
|
Concept
|
Liposomes
|
|
Concept
|
Liver Neoplasms
|
|
Concept
|
Immunotherapy
|
|
Concept
|
Infusions, Parenteral
|
|
Concept
|
Insurance, Health
|
|
Concept
|
Efficiency
|
|
Concept
|
Hospitalization
|
|
Concept
|
Erythropoiesis
|
|
Concept
|
Hydrocortisone
|
|
Concept
|
Hydroxamic Acids
|
|
Concept
|
Hyperbilirubinemia
|
|
Concept
|
Hypnotics and Sedatives
|
|
Concept
|
Feces
|
|
Concept
|
Flow Cytometry
|
|
Concept
|
Industry
|
|
Concept
|
Infusions, Intravenous
|
|
Concept
|
Insurance
|
|
Concept
|
Intercalating Agents
|
|
Concept
|
Gene Amplification
|
|
Concept
|
Germ Cells
|
|
Concept
|
Glutathione
|
|
Concept
|
Lactones
|
|
Concept
|
Leukocytes, Mononuclear
|
|
Concept
|
Medicare
|
|
Concept
|
Health Services Accessibility
|
|
Concept
|
Gastrointestinal Hemorrhage
|
|
Concept
|
Luminescent Measurements
|
|
Concept
|
Maryland
|
|
Concept
|
Hepatitis C
|
|
Concept
|
Carcinoma, Hepatocellular
|
|
Concept
|
Maytansine
|
|
Concept
|
Medical Records
|
|
Concept
|
Metformin
|
|
Concept
|
Hydroxytestosterones
|
|
Concept
|
Microfilament Proteins
|
|
Concept
|
Pharmacogenetics
|
|
Concept
|
Pilot Projects
|
|
Concept
|
Liver Function Tests
|
|
Concept
|
Lymphopenia
|
|
Concept
|
Macaca mulatta
|
|
Concept
|
Midazolam
|
|
Concept
|
Models, Genetic
|
|
Concept
|
Models, Theoretical
|
|
Concept
|
Neutropenia
|
|
Concept
|
Nogalamycin
|
|
Concept
|
Medication Errors
|
|
Concept
|
Estrogen Antagonists
|
|
Concept
|
Professional Practice
|
|
Concept
|
Imides
|
|
Concept
|
Immunohistochemistry
|
|
Concept
|
Indazoles
|
|
Concept
|
Insurance Claim Review
|
|
Concept
|
Molecular Sequence Data
|
|
Concept
|
Oxidoreductases, N-Demethylating
|
|
Concept
|
Pain
|
|
Concept
|
Pancreatic Neoplasms
|
|
Concept
|
Meperidine
|
|
Concept
|
Methotrexate
|
|
Concept
|
Mice, Inbred C57BL
|
|
Concept
|
Microsomes, Liver
|
|
Concept
|
Random Allocation
|
|
Concept
|
Mitoxantrone
|
|
Concept
|
Mycosis Fungoides
|
|
Concept
|
Cricetinae
|
|
Concept
|
Health Policy
|
|
Concept
|
Hot Temperature
|
|
Concept
|
Patents as Topic
|
|
Concept
|
Patient Education as Topic
|
|
Concept
|
Rheumatology
|
|
Concept
|
Kidney Function Tests
|
|
Concept
|
Neutrophils
|
|
Concept
|
Leukemia L1210
|
|
Concept
|
Ovarian Neoplasms
|
|
Concept
|
Pain, Postoperative
|
|
Concept
|
Ligands
|
|
Concept
|
Lung Neoplasms
|
|
Concept
|
Oxycodone
|
|
Concept
|
Melphalan
|
|
Concept
|
Patient Acceptance of Health Care
|
|
Concept
|
Practice Patterns, Physicians'
|
|
Concept
|
Phenylurea Compounds
|
|
Concept
|
Morpholines
|
|
Concept
|
Motivation
|
|
Concept
|
Mouth Mucosa
|
|
Concept
|
Fear
|
|
Concept
|
Pharmacy and Therapeutics Committee
|
|
Concept
|
Prejudice
|
|
Concept
|
Drug Prescriptions
|
|
Concept
|
Probability
|
|
Concept
|
Prednisone
|
|
Concept
|
Epoprostenol
|
|
Concept
|
Prostatic Neoplasms
|
|
Concept
|
Thromboembolism
|
|
Concept
|
Protease Inhibitors
|
|
Concept
|
Frozen Sections
|
|
Concept
|
Hodgkin Disease
|
|
Concept
|
Troleandomycin
|
|
Concept
|
Hyponatremia
|
|
Concept
|
Idoxuridine
|
|
Concept
|
Imipramine
|
|
Concept
|
Immunoenzyme Techniques
|
|
Concept
|
Recurrence
|
|
Concept
|
Regression Analysis
|
|
Concept
|
Research Personnel
|
|
Concept
|
Guanine
|
|
Concept
|
Head and Neck Neoplasms
|
|
Concept
|
Reimbursement, Incentive
|
|
Concept
|
Research Support as Topic
|
|
Concept
|
Risk Factors
|
|
Concept
|
Verapamil
|
|
Concept
|
Quality of Life
|
|
Concept
|
Interferon-gamma
|
|
Concept
|
Interinstitutional Relations
|
|
Concept
|
Intestinal Absorption
|
|
Concept
|
Intestinal Mucosa
|
|
Concept
|
Soft Tissue Neoplasms
|
|
Concept
|
Carcinoma, Merkel Cell
|
|
Concept
|
Cohort Studies
|
|
Concept
|
Genes, ras
|
|
Concept
|
Ribonucleosides
|
|
Concept
|
Leukemia, B-Cell
|
|
Concept
|
Interleukin-6
|
|
Concept
|
Shivering
|
|
Concept
|
Health Knowledge, Attitudes, Practice
|
|
Concept
|
Stomatitis
|
|
Concept
|
Risk
|
|
Concept
|
Sensitivity and Specificity
|
|
Concept
|
Thymidine
|
|
Concept
|
Societies, Medical
|
|
Concept
|
Humans
|
|
Concept
|
Leukocyte Count
|
|
Concept
|
Leukopenia
|
|
Concept
|
Complement C1q
|
|
Concept
|
Body Mass Index
|
|
Concept
|
Incidence
|
|
Concept
|
Linear Models
|
|
Concept
|
Bone Marrow Transplantation
|
|
Concept
|
Organizational Policy
|
|
Concept
|
Testicular Neoplasms
|
|
Concept
|
Thalidomide
|
|
Concept
|
Statistics as Topic
|
|
Concept
|
Informed Consent
|
|
Concept
|
Injections, Intravenous
|
|
Concept
|
Interferon Type I
|
|
Concept
|
Tetrahydrofolates
|
|
Concept
|
Lymphoma, T-Cell, Cutaneous
|
|
Concept
|
CHO Cells
|
|
Concept
|
Motor Neuron Disease
|
|
Concept
|
Truth Disclosure
|
|
Concept
|
United States
|
|
Concept
|
United States Food and Drug Administration
|
|
Concept
|
Syndrome
|
|
Concept
|
Program Development
|
|
Concept
|
Uridine Diphosphate
|
|
Concept
|
Clinical Trials, Phase I as Topic
|
|
Concept
|
Hypertrophy, Right Ventricular
|
|
Concept
|
Receptors, IgG
|
|
Concept
|
Warfarin
|
|
Concept
|
Tamoxifen
|
|
Concept
|
Vasodilator Agents
|
|
Concept
|
Drug Design
|
|
Concept
|
Isoquinolines
|
|
Concept
|
Ketoconazole
|
|
Concept
|
Germ-Line Mutation
|
|
Concept
|
Multicenter Studies as Topic
|
|
Concept
|
Leukemia, Lymphocytic, Chronic, B-Cell
|
|
Concept
|
Isotretinoin
|
|
Concept
|
Mercaptopurine
|
|
Concept
|
Sulfotransferases
|
|
Concept
|
Leukemia, Myeloid
|
|
Concept
|
Lung
|
|
Concept
|
Lymphoma, Follicular
|
|
Concept
|
Thyroxine
|
|
Concept
|
Carcinoma, Neuroendocrine
|
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
|
Concept
|
Oncogene Proteins, Fusion
|
|
Concept
|
Proportional Hazards Models
|
|
Concept
|
Randomized Controlled Trials as Topic
|
|
Concept
|
Risk Assessment
|
|
Concept
|
Blood Pressure Monitoring, Ambulatory
|
|
Concept
|
CD56 Antigen
|
|
Concept
|
Developed Countries
|
|
Concept
|
Disease Management
|
|
Concept
|
Myeloablative Agonists
|
|
Concept
|
Receptors, Interleukin-6
|
|
Concept
|
Reverse Transcriptase Polymerase Chain Reaction
|
|
Concept
|
Oligodeoxyribonucleotides, Antisense
|
|
Concept
|
Multifactorial Inheritance
|
|
Concept
|
Glucuronic Acid
|
|
Concept
|
Mitogen-Activated Protein Kinases
|
|
Concept
|
Vinca Alkaloids
|
|
Concept
|
Vitamins
|
|
Concept
|
Werner Syndrome
|
|
Concept
|
Treatment Refusal
|
|
Concept
|
Myosin Type II
|
|
Concept
|
Principal Component Analysis
|
|
Concept
|
Propofol
|
|
Concept
|
Global Health
|
|
Concept
|
Arylsulfotransferase
|
|
Concept
|
Bias
|
|
Concept
|
Prevalence
|
|
Concept
|
DNA, Antisense
|
|
Concept
|
Ethical Review
|
|
Concept
|
Medicine
|
|
Concept
|
Mephenytoin
|
|
Concept
|
Metabolic Clearance Rate
|
|
Concept
|
Immunocompromised Host
|
|
Concept
|
Receptors, Interleukin-2
|
|
Concept
|
Leukemia, Prolymphocytic
|
|
Concept
|
Observer Variation
|
|
Concept
|
Pentostatin
|
|
Concept
|
2-Chloroadenosine
|
|
Concept
|
Drug Costs
|
|
Concept
|
Radiosurgery
|
|
Concept
|
Fluvoxamine
|
|
Concept
|
Lymphatic Metastasis
|
|
Concept
|
Lymphoma
|
|
Concept
|
Microsomes
|
|
Concept
|
Morphine
|
|
Concept
|
Leukemia, Myeloid, Acute
|
|
Concept
|
Causality
|
|
Concept
|
Chi-Square Distribution
|
|
Concept
|
Least-Squares Analysis
|
|
Concept
|
Lymphocytes, Tumor-Infiltrating
|
|
Concept
|
Paclitaxel
|
|
Concept
|
Comorbidity
|
|
Concept
|
Ethics, Research
|
|
Concept
|
Private Sector
|
|
Concept
|
Rats, Sprague-Dawley
|
|
Concept
|
Rats, Wistar
|
|
Concept
|
Clinical Trials, Phase II as Topic
|
|
Concept
|
Case-Control Studies
|
|
Concept
|
Human Genome Project
|
|
Concept
|
Prostate-Specific Antigen
|
|
Concept
|
Protein Structure, Tertiary
|
|
Concept
|
Receptors, Endothelin
|
|
Concept
|
Postmenopause
|
|
Concept
|
Medical Oncology
|
|
Concept
|
Melanoma
|
|
Concept
|
Menopause
|
|
Concept
|
Genes, Reporter
|
|
Concept
|
Microtubules
|
|
Concept
|
Paraffin Embedding
|
|
Concept
|
Treatment Outcome
|
|
Concept
|
National Institutes of Health (U.S.)
|
|
Concept
|
Neoplasm Metastasis
|
|
Concept
|
Neoplasm Recurrence, Local
|
|
Concept
|
Neoplasms, Experimental
|
|
Concept
|
Oligodeoxyribonucleotides
|
|
Concept
|
Consensus Sequence
|
|
Concept
|
Neurites
|
|
Concept
|
Tissue Fixation
|
|
Concept
|
Point Mutation
|
|
Concept
|
Interferon-alpha
|
|
Concept
|
Nedocromil
|
|
Concept
|
Health Care Costs
|
|
Concept
|
Gene Deletion
|
|
Concept
|
Sequence Deletion
|
|
Concept
|
Mice, Knockout
|
|
Concept
|
Receptors, Growth Factor
|
|
Concept
|
DNA, Complementary
|
|
Concept
|
Cell Proliferation
|
|
Concept
|
Patient-Centered Care
|
|
Concept
|
Dinucleotide Repeats
|
|
Concept
|
Neoplasms, Squamous Cell
|
|
Concept
|
Sample Size
|
|
Concept
|
Disease Progression
|
|
Concept
|
Evolution, Molecular
|
|
Concept
|
ras Proteins
|
|
Concept
|
Hepatocyte Nuclear Factor 1-alpha
|
|
Concept
|
Decision Support Systems, Clinical
|
|
Concept
|
Sepsis
|
|
Concept
|
Rats, Inbred Dahl
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
Cytochrome P-450 CYP2D6
|
|
Concept
|
Kv1.3 Potassium Channel
|
|
Concept
|
Cyclohexenes
|
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
|
Concept
|
Hepatocytes
|
|
Concept
|
Multidrug Resistance-Associated Proteins
|
|
Concept
|
Venous Thromboembolism
|
|
Concept
|
Cross-Over Studies
|
|
Concept
|
Analgesics, Non-Narcotic
|
|
Concept
|
Osteolysis
|
|
Concept
|
Disclosure
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Concept
|
Myosin Heavy Chains
|
|
Concept
|
Public Sector
|
|
Concept
|
Parkinson Disease
|
|
Concept
|
Metabolome
|
|
Concept
|
Cladribine
|
|
Concept
|
In Situ Hybridization, Fluorescence
|
|
Concept
|
Comprehension
|
|
Concept
|
Federal Government
|
|
Concept
|
Organizations, Nonprofit
|
|
Concept
|
Patient Protection and Affordable Care Act
|
|
Concept
|
Topoisomerase I Inhibitors
|
|
Concept
|
Therapeutic Human Experimentation
|
|
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
|
Concept
|
Endostatins
|
|
Concept
|
Receptors, G-Protein-Coupled
|
|
Concept
|
Nontherapeutic Human Experimentation
|
|
Concept
|
Equilibrative Nucleoside Transporter 1
|
|
Concept
|
Epothilones
|
|
Concept
|
Trust
|
|
Concept
|
History, 21st Century
|
|
Concept
|
Renal Insufficiency, Chronic
|
|
Concept
|
Hepatocyte Nuclear Factor 1
|
|
Concept
|
Lactams, Macrocyclic
|
|
Concept
|
Tumor Burden
|
|
Concept
|
Carcinoma, Small Cell
|
|
Concept
|
Megestrol Acetate
|
|
Concept
|
Area Under Curve
|
|
Concept
|
Budesonide
|
|
Concept
|
Proto-Oncogene Proteins c-raf
|
|
Concept
|
Amino Acid Substitution
|
|
Concept
|
Proto-Oncogene Proteins B-raf
|
|
Concept
|
Cultural Diversity
|
|
Concept
|
Patient Participation
|
|
Concept
|
Oligonucleotide Array Sequence Analysis
|
|
Concept
|
3' Untranslated Regions
|
|
Concept
|
RecQ Helicases
|
|
Concept
|
Glucuronides
|
|
Concept
|
Evidence-Based Medicine
|
|
Concept
|
Loss of Heterozygosity
|
|
Concept
|
Personal Autonomy
|
|
Concept
|
Health Care Sector
|
|
Concept
|
Perioperative Care
|
|
Concept
|
Sirolimus
|
|
Concept
|
Allelic Imbalance
|
|
Concept
|
Antineoplastic Protocols
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p21
|
|
Concept
|
Proto-Oncogene Proteins c-ret
|
|
Concept
|
Pharmacists
|
|
Concept
|
Physicians
|
|
Concept
|
Platelet Count
|
|
Concept
|
Platinum
|
|
Concept
|
Podophyllotoxin
|
|
Concept
|
Polyethylene Glycols
|
|
Concept
|
Organic Anion Transporters, Sodium-Independent
|
|
Concept
|
Promoter Regions, Genetic
|
|
Concept
|
Mice
|
|
Concept
|
Mucositis
|
|
Concept
|
Prostate
|
|
Concept
|
Pyrazoles
|
|
Concept
|
Rectum
|
|
Concept
|
Pyrroles
|
|
Concept
|
Surveys and Questionnaires
|
|
Concept
|
National Cancer Institute (U.S.)
|
|
Concept
|
Sarcoma
|
|
Concept
|
Severity of Illness Index
|
|
Concept
|
Tandem Mass Spectrometry
|
|
Concept
|
Research Design
|
|
Concept
|
RNA, Messenger
|
|
Concept
|
Schools, Medical
|
|
Concept
|
Stomach Neoplasms
|
|
Concept
|
Sulfonamides
|
|
Concept
|
Taiwan
|
|
Concept
|
Testosterone
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Concept
|
Taxoids
|
|
Concept
|
Pyrazolones
|
|
Concept
|
Luciferases, Firefly
|
|
Concept
|
Rats
|
|
Concept
|
Class I Phosphatidylinositol 3-Kinases
|
|
Concept
|
TOR Serine-Threonine Kinases
|
|
Concept
|
Adenosine A2 Receptor Antagonists
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Human Umbilical Vein Endothelial Cells
|
|
Concept
|
Sex Factors
|
|
Concept
|
Skin Neoplasms
|
|
Concept
|
Stereoisomerism
|
|
Concept
|
Valproic Acid
|
|
Concept
|
Vincristine
|
|
Concept
|
Vitamin D
|
|
Concept
|
Adaptor Proteins, Signal Transducing
|
|
Concept
|
Suramin
|
|
Concept
|
Blotting, Western
|
|
Concept
|
Colorectal Neoplasms
|
|
Concept
|
Models, Statistical
|
|
Concept
|
Epirubicin
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p15
|
|
Concept
|
Selection Bias
|
|
Concept
|
Life Tables
|
|
Concept
|
Multivariate Analysis
|
|
Concept
|
Logistic Models
|
|
Concept
|
Survival Analysis
|
|
Concept
|
DNA Copy Number Variations
|
|
Concept
|
Thymidylate Synthase
|
|
Concept
|
Thyroid Neoplasms
|
|
Concept
|
Lymphoma, B-Cell
|
|
Concept
|
CD4-CD8 Ratio
|
|
Concept
|
Cyclosporine
|
|
Concept
|
Electronic Health Records
|
|
Concept
|
Drug Monitoring
|
|
Concept
|
Vinblastine
|
|
Concept
|
Reproducibility of Results
|
|
Concept
|
Zidovudine
|
|
Concept
|
Patient Satisfaction
|
|
Concept
|
Treatment Failure
|
|
Concept
|
Genetic Therapy
|
|
Concept
|
Molecular Structure
|
|
Concept
|
Clinical Medicine
|
|
Concept
|
Topoisomerase Inhibitors
|
|
Concept
|
Survival Rate
|
|
Concept
|
Odds Ratio
|
|
Concept
|
Lymphocyte Subsets
|
|
Concept
|
Polymerase Chain Reaction
|
|
Concept
|
Granulocyte Colony-Stimulating Factor
|
|
Concept
|
Conflict of Interest
|
|
Concept
|
ATP-Binding Cassette Transporters
|
|
Concept
|
Food-Drug Interactions
|
|
Concept
|
Patient Selection
|
|
Concept
|
Receptor, ErbB-2
|
|
Concept
|
Lymphoma, Large B-Cell, Diffuse
|
|
Concept
|
Cost Sharing
|
|
Concept
|
Cyclin-Dependent Kinases
|
|
Concept
|
Intellectual Property
|
|
Concept
|
Menogaril
|
|
Concept
|
HIV Protease Inhibitors
|
|
Concept
|
Clinical Trials, Phase III as Topic
|
|
Concept
|
DNA Methylation
|
|
Concept
|
Naphthalimides
|
|
Concept
|
Karnofsky Performance Status
|
|
Concept
|
Metabolic Networks and Pathways
|
|
Concept
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
|
Concept
|
Dietary Supplements
|
|
Concept
|
Proto-Oncogene Proteins c-met
|
|
Concept
|
Interleukin-17
|
|
Concept
|
Receptors, Calcitriol
|
|
Concept
|
Advisory Committees
|
|
Concept
|
Statistics, Nonparametric
|
|
Concept
|
HSP90 Heat-Shock Proteins
|
|
Concept
|
Hematologic Neoplasms
|
|
Concept
|
Histone Deacetylase Inhibitors
|
|
Concept
|
Gadolinium DTPA
|
|
Concept
|
O(6)-Methylguanine-DNA Methyltransferase
|
|
Concept
|
Phosphatidylinositol 3-Kinases
|
|
Concept
|
Withholding Treatment
|
|
Concept
|
Receptor, trkA
|
|
Concept
|
MAP Kinase Signaling System
|
|
Concept
|
Hearing Loss
|
|
Concept
|
Receptor, EphA5
|
|
Concept
|
History, 20th Century
|
|
Concept
|
Organic Anion Transporters
|
|
Concept
|
Tubulin Modulators
|
|
Concept
|
Medical Order Entry Systems
|
|
Concept
|
Comparative Effectiveness Research
|
|
Concept
|
Ethics Committees, Research
|
|
Concept
|
Janus Kinase 2
|
|
Concept
|
Genome-Wide Association Study
|
|
Concept
|
Hep G2 Cells
|
|
Concept
|
Pathology, Molecular
|
|
Concept
|
Precision Medicine
|
|
Concept
|
Citrus paradisi
|
|
Concept
|
Control Groups
|
|
Concept
|
Antibodies, Monoclonal, Murine-Derived
|
|
Concept
|
Pain Management
|
|
Concept
|
Ribosomal Protein S6 Kinases, 70-kDa
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Programmed Cell Death 1 Receptor
|
|
Concept
|
Depsipeptides
|
|
Concept
|
Hepatic Insufficiency
|
|
Concept
|
Renal Insufficiency
|
|
Concept
|
Cytochrome P-450 CYP3A
|
|
Concept
|
Kaplan-Meier Estimate
|
|
Concept
|
Healthcare Disparities
|
|
Concept
|
Drug Discovery
|
|
Concept
|
Topoisomerase II Inhibitors
|
|
Concept
|
Anemia, Sickle Cell
|
|
Concept
|
Anthracenes
|
|
Concept
|
Immunotoxins
|
|
Concept
|
Hypolipidemic Agents
|
|
Concept
|
Antineoplastic Agents, Phytogenic
|
|
Concept
|
Axons
|
|
Concept
|
Benzenesulfonates
|
|
Concept
|
Binding, Competitive
|
|
Concept
|
Blood Cell Count
|
|
Concept
|
Body Surface Area
|
|
Concept
|
Brain Neoplasms
|
|
Concept
|
Carbolines
|
|
Concept
|
Cardiovascular Agents
|
|
Concept
|
Catechin
|
|
Concept
|
Catechol O-Methyltransferase
|
|
Concept
|
Chlorambucil
|
|
Concept
|
Clinical Trials as Topic
|
|
Concept
|
Cytosine
|
|
Concept
|
Data Collection
|
|
Concept
|
Data Interpretation, Statistical
|
|
Concept
|
Deoxycytidine
|
|
Concept
|
Drug Eruptions
|
|
Concept
|
Dietary Fats
|
|
Concept
|
Disease Models, Animal
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Drug Screening Assays, Antitumor
|
|
Concept
|
Follow-Up Studies
|
|
Concept
|
Genetic Testing
|
|
Concept
|
Glucuronates
|
|
Concept
|
Government
|
|
Concept
|
Health Personnel
|
|
Concept
|
Hyperglycemia
|
|
Concept
|
Indenes
|
|
Concept
|
Injections, Subcutaneous
|
|
Concept
|
Insurance Benefits
|
|
Concept
|
Insurance, Health, Reimbursement
|
|
Concept
|
Leukemia, Hairy Cell
|
|
Concept
|
Leukemia, Monocytic, Acute
|
|
Concept
|
Liver Diseases
|
|
Concept
|
Longitudinal Studies
|
|
Concept
|
Lymphocytes
|
|
Concept
|
Lymphoma, Non-Hodgkin
|
|
Concept
|
Magnetic Resonance Imaging
|
|
Concept
|
Models, Biological
|
|
Concept
|
Monocytes
|
|
Concept
|
Morphine Derivatives
|
|
Concept
|
Neoplasm Invasiveness
|
|
Concept
|
Neoplasms, Glandular and Epithelial
|
|
Concept
|
Niacinamide
|
|
Concept
|
Nicotine
|
|
Concept
|
Nitrophenols
|
|
Concept
|
Oligonucleotides
|
|
Concept
|
Omeprazole
|
|
Concept
|
Orphan Drug Production
|
|
Concept
|
Patient Compliance
|
|
Concept
|
Physician-Patient Relations
|
|
Concept
|
Platelet Aggregation Inhibitors
|
|
Concept
|
Predictive Value of Tests
|
|
Concept
|
Professional Staff Committees
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Retrospective Studies
|
|
Concept
|
Social Perception
|
|
Concept
|
T-Lymphocytes
|
|
Concept
|
Tramadol
|
|
Concept
|
Translocation, Genetic
|
|
Concept
|
Glucuronosyltransferase
|
|
Concept
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
|
Concept
|
Granulocyte-Macrophage Colony-Stimulating Factor
|
|
Concept
|
Databases, Factual
|
|
Concept
|
Oligonucleotides, Antisense
|
|
Concept
|
Anticarcinogenic Agents
|
|
Concept
|
Hospital Mortality
|
|
Concept
|
Conserved Sequence
|
|
Concept
|
Greenhouse Effect
|
|
Concept
|
Pharmacoepidemiology
|
|
Concept
|
DNA Primers
|
|
Concept
|
Neuroendocrine Tumors
|
|
Concept
|
Disease-Free Survival
|
|
Concept
|
Anti-Asthmatic Agents
|
|
Concept
|
Macrolides
|
|
Concept
|
Point-of-Care Systems
|
|
Concept
|
Genetic Predisposition to Disease
|
|
Concept
|
Polymorphism, Single Nucleotide
|
|
Concept
|
Membrane Transport Proteins
|
|
Concept
|
Organic Cation Transporter 1
|
|
Concept
|
Genetic Privacy
|
|
Concept
|
Consent Forms
|
|
Concept
|
MicroRNAs
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Concept
|
Transforming Growth Factor beta3
|
|
Concept
|
Medication Adherence
|
|
Concept
|
Off-Label Use
|
|
Concept
|
Drug Recalls
|
|
Academic Article
|
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Phase I study of amonafide dosing based on acetylator phenotype.
|
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
|
Academic Article
|
Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion.
|
|
Academic Article
|
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
|
|
Academic Article
|
Individualizing dosing of cancer chemotherapy.
|
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
|
|
Academic Article
|
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.
|
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
|
Academic Article
|
Promising new agents in oncologic treatment.
|
|
Academic Article
|
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
|
|
Academic Article
|
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
|
|
Academic Article
|
Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.
|
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
|
Academic Article
|
Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients.
|
|
Academic Article
|
Clinical pharmacology of camptothecins.
|
|
Academic Article
|
Limited sampling model for area under the concentration time curve of total topotecan.
|
|
Academic Article
|
Pharmacogenetics and cancer chemotherapy.
|
|
Academic Article
|
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
|
|
Academic Article
|
Pharmacogenetics in cancer etiology and chemotherapy.
|
|
Academic Article
|
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
|
|
Academic Article
|
A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors.
|
|
Academic Article
|
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.
|
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
|
Academic Article
|
Update on pharmacogenetics in cancer chemotherapy.
|
|
Academic Article
|
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study.
|
|
Academic Article
|
UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
|
|
Academic Article
|
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
|
|
Academic Article
|
Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.
|
|
Academic Article
|
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
|
|
Academic Article
|
Anticancer drug discovery and development throughout the world.
|
|
Academic Article
|
Pharmacogenetics in cancer treatment.
|
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
|
|
Academic Article
|
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
|
|
Academic Article
|
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
|
|
Academic Article
|
Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
|
|
Academic Article
|
In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes.
|
|
Academic Article
|
Pharmacogenomics: road to anticancer therapeutics nirvana?
|
|
Academic Article
|
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
|
|
Academic Article
|
Paradoxical relationship between acetylator phenotype and amonafide toxicity.
|
|
Academic Article
|
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.
|
|
Academic Article
|
"Irinogenetics" and UGT1A: from genotypes to haplotypes.
|
|
Academic Article
|
Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
|
|
Academic Article
|
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer.
|
|
Academic Article
|
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
|
|
Academic Article
|
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
|
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
|
Academic Article
|
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
|
|
Academic Article
|
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
|
|
Academic Article
|
UGT pharmacogenomics: implications for cancer risk and cancer therapeutics.
|
|
Academic Article
|
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
|
|
Academic Article
|
Pharmacokinetic variability of anticancer agents.
|
|
Academic Article
|
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
|
|
Academic Article
|
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Phase II oncology trials: let's be positive.
|
|
Academic Article
|
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
|
|
Academic Article
|
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
|
|
Academic Article
|
Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor.
|
|
Academic Article
|
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.
|
|
Academic Article
|
Finding the right dose.
|
|
Academic Article
|
Pharmacogenomics: challenges and opportunities.
|
|
Academic Article
|
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
|
|
Academic Article
|
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing.
|
|
Academic Article
|
Effects of green tea compounds on irinotecan metabolism.
|
|
Academic Article
|
Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs.
|
|
Academic Article
|
Lack of association between common polymorphisms in UGT1A9 and gene expression and activity.
|
|
Academic Article
|
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity.
|
|
Academic Article
|
The pharmacogenetics research network: from SNP discovery to clinical drug response.
|
|
Academic Article
|
Interpreting P values in pharmacogenetic studies: a call for process and perspective.
|
|
Academic Article
|
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
|
|
Academic Article
|
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
|
|
Academic Article
|
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
|
|
Academic Article
|
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
|
|
Academic Article
|
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine.
|
|
Academic Article
|
Exploring the relationship between polymorphic (TG/CA)n repeats in intron 1 regions and gene expression.
|
|
Academic Article
|
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
|
|
Academic Article
|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
|
|
Academic Article
|
A survey of the population genetic variation in the human kinome.
|
|
Academic Article
|
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
|
|
Academic Article
|
Etoposide pathway.
|
|
Academic Article
|
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
|
|
Academic Article
|
Hairy cell leukemia. Current management.
|
|
Academic Article
|
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
|
|
Academic Article
|
A pharmacogenetic study of vorinostat glucuronidation.
|
|
Academic Article
|
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
|
|
Academic Article
|
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
|
|
Academic Article
|
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
|
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
|
Academic Article
|
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.
|
|
Academic Article
|
Recommended changes to oncology clinical trial design: revolution or evolution?
|
|
Academic Article
|
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.
|
|
Academic Article
|
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
|
|
Academic Article
|
Models of excellence: improving oncology drug development.
|
|
Academic Article
|
Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.
|
|
Academic Article
|
Why RECIST works and why it should stay--reply to counterpoint.
|
|
Academic Article
|
Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin.
|
|
Academic Article
|
Correspondence re: Xiu F. Hu et al., Combined use of cyclosporin A and verapamil in modulating multidrug resistance in human leukemia cell lines. Cancer Res., 50: 2953-2957, 1990.
|
|
Academic Article
|
Optimising the design of phase II oncology trials: the importance of randomisation.
|
|
Academic Article
|
Phase I and pharmacological study of vinblastine by prolonged continuous infusion.
|
|
Academic Article
|
Phase I study of escalating does of carboplatin.
|
|
Academic Article
|
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.
|
|
Academic Article
|
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
|
|
Academic Article
|
A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
|
|
Academic Article
|
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
|
Academic Article
|
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
|
|
Academic Article
|
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.
|
|
Academic Article
|
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
|
|
Academic Article
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
|
Academic Article
|
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
|
|
Academic Article
|
Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
|
|
Academic Article
|
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.
|
|
Academic Article
|
A population model for the leukopenic effect of etoposide.
|
|
Academic Article
|
Bootstrap validation of pharmacodynamic models defined via stepwise linear regression.
|
|
Academic Article
|
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
|
|
Academic Article
|
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
|
|
Academic Article
|
Pharmacogenetics and pharmacogenomics of anticancer agents.
|
|
Academic Article
|
Dose-escalation models for combination phase I trials in oncology.
|
|
Academic Article
|
Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
|
|
Academic Article
|
Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.
|
|
Academic Article
|
Analysis of the yield of phase II combination therapy trials in medical oncology.
|
|
Academic Article
|
Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?
|
|
Academic Article
|
RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.
|
|
Academic Article
|
Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
|
|
Academic Article
|
Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy.
|
|
Academic Article
|
Interpatient and intrapatient variability in vinblastine pharmacokinetics.
|
|
Academic Article
|
Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer.
|
|
Academic Article
|
Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns.
|
|
Academic Article
|
Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours.
|
|
Academic Article
|
A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients.
|
|
Academic Article
|
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
|
|
Academic Article
|
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital.
|
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
|
Academic Article
|
Modulation of vinblastine resistance with cyclosporine: a phase I study.
|
|
Academic Article
|
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
|
|
Academic Article
|
Measuring response in a post-RECIST world: from black and white to shades of grey.
|
|
Academic Article
|
The role of pharmacogenetics in cancer therapeutics.
|
|
Academic Article
|
Pharmacodynamics in cancer therapy.
|
|
Academic Article
|
Pharmacogenetic pathway analysis of irinotecan.
|
|
Academic Article
|
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
|
|
Academic Article
|
Creating and evaluating genetic tests predictive of drug response.
|
|
Academic Article
|
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
|
|
Academic Article
|
Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
|
|
Academic Article
|
A limited sampling strategy for cyclophosphamide pharmacokinetics.
|
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
|
Academic Article
|
Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
|
|
Academic Article
|
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
|
|
Academic Article
|
Unsupported off-label chemotherapy in metastatic colon cancer.
|
|
Academic Article
|
A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection.
|
|
Academic Article
|
CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality.
|
|
Academic Article
|
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
|
|
Academic Article
|
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
|
Academic Article
|
Targeted therapies: redefining the primary objective of phase I oncology trials.
|
|
Academic Article
|
Meaningful use of pharmacogenetics.
|
|
Academic Article
|
Tumour heterogeneity in the clinic.
|
|
Academic Article
|
Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.
|
|
Academic Article
|
Incorporating biomarkers into drug labeling.
|
|
Academic Article
|
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
|
|
Academic Article
|
Are drug labels static or dynamic?
|
|
Academic Article
|
Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression.
|
|
Academic Article
|
Unmet needs in preventing adverse drug-drug interactions.
|
|
Academic Article
|
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
|
|
Academic Article
|
Vemurafenib oral bioavailability: an insoluble problem.
|
|
Academic Article
|
The development of a financial toxicity patient-reported outcome in cancer: The COST measure.
|
|
Academic Article
|
Establishment of CYP2D6 reference samples by multiple validated genotyping platforms.
|
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
|
Academic Article
|
Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver.
|
|
Academic Article
|
Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.
|
|
Academic Article
|
Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.
|
|
Academic Article
|
In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.
|
|
Academic Article
|
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
|
|
Academic Article
|
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
|
Academic Article
|
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.
|
|
Academic Article
|
The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone.
|
|
Academic Article
|
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.
|
|
Academic Article
|
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
|
|
Academic Article
|
Interferon Alfa-2b Antibodies and Clinical Resistance in a Patient with Hairy Cell Leukemia.
|
|
Academic Article
|
Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients.
|
|
Academic Article
|
Genomewide Association Studies in Pharmacogenomics: Meeting Report of the NIH Pharmacogenomics Research Network-RIKEN (PGRN-RIKEN) Collaboration.
|
|
Academic Article
|
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
|
|
Academic Article
|
New feature: pathways and important genes from PharmGKB.
|
|
Academic Article
|
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
|
|
Academic Article
|
ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia.
|
|
Academic Article
|
Obviating the Need for Serial Biopsies Through Random Assignment.
|
|
Academic Article
|
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
|
|
Academic Article
|
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
|
|
Academic Article
|
Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.
|
|
Academic Article
|
Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
|
|
Academic Article
|
Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).
|
|
Academic Article
|
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).
|
|
Academic Article
|
Metabolism of megestrol acetate in vitro and the role of oxidative metabolites.
|
|
Academic Article
|
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).
|
|
Academic Article
|
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
|
|
Academic Article
|
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
|
|
Academic Article
|
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
|
|
Academic Article
|
Patient-provider communications about pharmacogenomic results increase patient recall of medication changes.
|
|
Academic Article
|
Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew.
|
|
Academic Article
|
Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib.
|
|
Academic Article
|
Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy.
|
|
Academic Article
|
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
|
|
Academic Article
|
Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients.
|
|
Academic Article
|
Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value.
|
|
Academic Article
|
Applied Clinical Pharmacology in a Crisis: Interleukin-6 Axis Blockade and COVID-19.
|
|
Academic Article
|
Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinib.
|
|
Academic Article
|
The Right Dose: From Phase I to Clinical Practice.
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
|
Academic Article
|
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
|
|
Academic Article
|
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
|
|
Academic Article
|
Clinically actionable genotypes for anticancer prescribing among >1500 patients with pharmacogenomic testing.
|
|
Academic Article
|
Lurbinectedin-induced thrombocytopenia: the role of body surface area.
|
|
Academic Article
|
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
|
|
Academic Article
|
The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force.
|
|
Academic Article
|
An Expanded Role for IRBs in the Oversight of Research Biopsies.
|
|
Academic Article
|
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
|
|
Academic Article
|
US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?
|
|
Concept
|
Clinical Decision-Making
|
|
Concept
|
Celecoxib
|
|
Concept
|
Bevacizumab
|
|
Concept
|
Everolimus
|
|
Concept
|
Imatinib Mesylate
|
|
Concept
|
Trastuzumab
|
|
Concept
|
Cetuximab
|
|
Concept
|
Rituximab
|
|
Concept
|
Capecitabine
|
|
Concept
|
Atazanavir Sulfate
|
|
Concept
|
Filgrastim
|
|
Concept
|
Abiraterone Acetate
|
|
Concept
|
Patient Reported Outcome Measures
|
|
Concept
|
Pharmacogenomic Variants
|
|
Concept
|
Pharmacogenomic Testing
|
|
Concept
|
Werner Syndrome Helicase
|
|
Concept
|
Equivalence Trials as Topic
|
|
Concept
|
Antineoplastic Agents, Immunological
|
|
Concept
|
Solute Carrier Organic Anion Transporter Family Member 1B3
|
|
Concept
|
Meaningful Use
|
|
Concept
|
Tertiary Care Centers
|
|
Concept
|
Patient Outcome Assessment
|
|
Concept
|
Prostatic Neoplasms, Castration-Resistant
|
|
Concept
|
Cytochrome P-450 CYP2C19
|
|
Concept
|
Cytochrome P-450 Enzyme Inhibitors
|
|
Concept
|
Familial Primary Pulmonary Hypertension
|
|
Concept
|
Cardiotoxicity
|
|
Concept
|
Cytochrome P-450 CYP2D6 Inhibitors
|
|
Concept
|
Cytochrome P-450 CYP3A Inhibitors
|
|
Concept
|
Cytochrome P-450 CYP2B6
|
|
Concept
|
Cytochrome P-450 CYP2C8
|
|
Concept
|
Cytochrome P-450 CYP2C9
|
|
Concept
|
In Vitro Techniques
|
|
Concept
|
Response Evaluation Criteria in Solid Tumors
|
|
Concept
|
Proton Magnetic Resonance Spectroscopy
|
|
Concept
|
ErbB Receptors
|
|
Academic Article
|
Do patent applications and Cooperative Research and Development Agreements between the National Cancer Institute and industry serve the public interest?
|